Back
Speaker illustration

Doctor Mazen Hanna

Cleveland Clinic Main Campus, Cleveland (United States of America)

Presentations

Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis

Event: ESC Congress 2025

Topic: Infiltrative Myocardial Disease

Session: Prognostication and treatment of transthyretin cardiac amyloidosis

Access
Like
Thumbnail

Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial

Event: ESC Congress 2025

Topic: Pharmacotherapy

Session: Multidisciplinary care in heart failure

Access
Like
Thumbnail

Expert exchange: treating hATTR polyneuropathy patients with a mixed phenotype (polyneuropathy and cardiomyopathy)

Event: ESC Congress 2024

Topic: Cardiovascular Disease in Special Populations

Session: Expert exchange: treating hATTR polyneuropathy patients with a mixed phenotype (polyneuropathy and cardiomyopathy)

Access
Like
Thumbnail

Expert exchange: treating hATTR polyneuropathy patients with a mixed phenotype (polyneuropathy and cardiomyopathy)

Event: ESC Congress 2024

Topic: Cardiovascular Disease in Special Populations

Session: Expert exchange: treating hATTR polyneuropathy patients with a mixed phenotype (polyneuropathy and cardiomyopathy)

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources